Cargando…

Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson’s Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance

OBJECTIVE: The aim of this study was to assess quantitatively the gait disorders in the daily lives of patients with Parkinson’s disease (PD) using with a newly developed portable gait rhythmogram (PGR), which has a trunk-mounted acceleration sensor and automatic gait-detection algorithm. METHODS: U...

Descripción completa

Detalles Bibliográficos
Autores principales: Iijima, Mutsumi, Mitoma, Hiroshi, Uchiyama, Shinichiro, Kitagawa, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5660685/
https://www.ncbi.nlm.nih.gov/pubmed/29114238
http://dx.doi.org/10.3389/fneur.2017.00542
_version_ 1783274337298546688
author Iijima, Mutsumi
Mitoma, Hiroshi
Uchiyama, Shinichiro
Kitagawa, Kazuo
author_facet Iijima, Mutsumi
Mitoma, Hiroshi
Uchiyama, Shinichiro
Kitagawa, Kazuo
author_sort Iijima, Mutsumi
collection PubMed
description OBJECTIVE: The aim of this study was to assess quantitatively the gait disorders in the daily lives of patients with Parkinson’s disease (PD) using with a newly developed portable gait rhythmogram (PGR), which has a trunk-mounted acceleration sensor and automatic gait-detection algorithm. METHODS: Using the PGR, we recorded the daily walking profiles of 14 PD patients before and after the addition or increase in dose of an MAO-B inhibitor (selegiline, average dose: 4.0 mg/day) as part of their medicine regimen, and evaluated their gait using the unified Parkinson’s disease rating scale (UPDRS) and scores from a freezing of gait (FOG) questionnaire. RESULTS: Before treatment with selegiline, the overall movements per 24 h was decreased below 0.41 m/s(2) (mean − 1.5 SD) in eight patients. The mean gait acceleration was decreased below 1.94 m/s(2) (mean − 2 SD) in 10 patients. The slope of the linear regression line was increased to 1.6 (mean + 1.5 SD) in eight patients. The cadence was increased to 124 steps/min (mean + 1.5 SD) in four patients. Based on continuous PGR recordings in the daily lives of the patients for 24 h, the addition or increase in dose of selegiline increased the amplitudes of gait accelerations in 4 of 10 patients (40.0%), widened the range of gait accelerations in 5 of 8 patients (62.5%), diminished the cadence in 4 of 4 patients (100%), and diminished the fluctuations in gait throughout the day in 12 of 14 patients (85.7%). The UPDRS III and FOG scores significantly improved after the addition or increase in dose of selegiline (p < 0.005, p < 0.01, respectively). However, changes in gait-related scores of UPDRS were not detected in six patients. CONCLUSION: Improvements in the gait fluctuations of PD patients after the addition or increase in dose of selegiline were detected using the PGR in the daily lives of the patients for 24 h. The PGR had a higher sensitivity for detecting the improvements than UPDRS scores.
format Online
Article
Text
id pubmed-5660685
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-56606852017-11-07 Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson’s Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance Iijima, Mutsumi Mitoma, Hiroshi Uchiyama, Shinichiro Kitagawa, Kazuo Front Neurol Neuroscience OBJECTIVE: The aim of this study was to assess quantitatively the gait disorders in the daily lives of patients with Parkinson’s disease (PD) using with a newly developed portable gait rhythmogram (PGR), which has a trunk-mounted acceleration sensor and automatic gait-detection algorithm. METHODS: Using the PGR, we recorded the daily walking profiles of 14 PD patients before and after the addition or increase in dose of an MAO-B inhibitor (selegiline, average dose: 4.0 mg/day) as part of their medicine regimen, and evaluated their gait using the unified Parkinson’s disease rating scale (UPDRS) and scores from a freezing of gait (FOG) questionnaire. RESULTS: Before treatment with selegiline, the overall movements per 24 h was decreased below 0.41 m/s(2) (mean − 1.5 SD) in eight patients. The mean gait acceleration was decreased below 1.94 m/s(2) (mean − 2 SD) in 10 patients. The slope of the linear regression line was increased to 1.6 (mean + 1.5 SD) in eight patients. The cadence was increased to 124 steps/min (mean + 1.5 SD) in four patients. Based on continuous PGR recordings in the daily lives of the patients for 24 h, the addition or increase in dose of selegiline increased the amplitudes of gait accelerations in 4 of 10 patients (40.0%), widened the range of gait accelerations in 5 of 8 patients (62.5%), diminished the cadence in 4 of 4 patients (100%), and diminished the fluctuations in gait throughout the day in 12 of 14 patients (85.7%). The UPDRS III and FOG scores significantly improved after the addition or increase in dose of selegiline (p < 0.005, p < 0.01, respectively). However, changes in gait-related scores of UPDRS were not detected in six patients. CONCLUSION: Improvements in the gait fluctuations of PD patients after the addition or increase in dose of selegiline were detected using the PGR in the daily lives of the patients for 24 h. The PGR had a higher sensitivity for detecting the improvements than UPDRS scores. Frontiers Media S.A. 2017-10-24 /pmc/articles/PMC5660685/ /pubmed/29114238 http://dx.doi.org/10.3389/fneur.2017.00542 Text en Copyright © 2017 Iijima, Mitoma, Uchiyama and Kitagawa. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Iijima, Mutsumi
Mitoma, Hiroshi
Uchiyama, Shinichiro
Kitagawa, Kazuo
Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson’s Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance
title Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson’s Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance
title_full Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson’s Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance
title_fullStr Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson’s Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance
title_full_unstemmed Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson’s Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance
title_short Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson’s Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance
title_sort long-term monitoring gait analysis using a wearable device in daily lives of patients with parkinson’s disease: the efficacy of selegiline hydrochloride for gait disturbance
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5660685/
https://www.ncbi.nlm.nih.gov/pubmed/29114238
http://dx.doi.org/10.3389/fneur.2017.00542
work_keys_str_mv AT iijimamutsumi longtermmonitoringgaitanalysisusingawearabledeviceindailylivesofpatientswithparkinsonsdiseasetheefficacyofselegilinehydrochlorideforgaitdisturbance
AT mitomahiroshi longtermmonitoringgaitanalysisusingawearabledeviceindailylivesofpatientswithparkinsonsdiseasetheefficacyofselegilinehydrochlorideforgaitdisturbance
AT uchiyamashinichiro longtermmonitoringgaitanalysisusingawearabledeviceindailylivesofpatientswithparkinsonsdiseasetheefficacyofselegilinehydrochlorideforgaitdisturbance
AT kitagawakazuo longtermmonitoringgaitanalysisusingawearabledeviceindailylivesofpatientswithparkinsonsdiseasetheefficacyofselegilinehydrochlorideforgaitdisturbance